(Q34572041)

3 August 2017

1 reference

title

New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer (English)

1 reference

3 August 2017

1 reference

1 reference

K D Holen

1

1 reference

3 August 2017

L B Saltz

series ordinal

2

1 reference

3 August 2017

publication date

1 May 2001

1 reference

Lancet Oncology Commission

3 August 2017

published in

1 reference

3 August 2017

volume

2

1 reference

3 August 2017

issue

5

1 reference

3 August 2017

page(s)

290-297

1 reference

Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900324-7

7 January 2021

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900324-7

7 January 2021

Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900324-7

7 January 2021

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900324-7

7 January 2021

Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900324-7

7 January 2021

Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900324-7

7 January 2021

Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900324-7

7 January 2021

The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900324-7

7 January 2021

A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900324-7

7 January 2021

Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900324-7

7 January 2021

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900324-7

7 January 2021

Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900324-7

7 January 2021

Phase I and pharmacokinetic trial of weekly CPT-11

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900324-7

7 January 2021

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900324-7

7 January 2021

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900324-7

7 January 2021

Irinotecan is an active agent in untreated patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900324-7

7 January 2021

Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900324-7

7 January 2021

Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900324-7

7 January 2021

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900324-7

7 January 2021

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900324-7

7 January 2021

Phase I study of oxaliplatin in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900324-7

7 January 2021

Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900324-7

7 January 2021

Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900324-7

7 January 2021

Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900324-7

7 January 2021

A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900324-7

7 January 2021

Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900324-7

7 January 2021

Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900324-7

7 January 2021

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900324-7

7 January 2021

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900324-7

7 January 2021

Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900324-7

7 January 2021

Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900324-7

7 January 2021

Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900324-7

7 January 2021

Raltitrexed (Tomudex) in combination with 5-fluorouracil for the treatment of patients with advanced colorectal cancer: preliminary results from phase I clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900324-7

7 January 2021

Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900324-7

7 January 2021

Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900324-7

7 January 2021

10.1016/S1470-2045(00)00324-7

Identifiers

DOI

1 reference

3 August 2017

1 reference